Exploring regulatory data sets of the Comirnaty vaccine - First part
A summary of posts
We have come to an end (for now) of our exploration of the regulatory data available at the time of licensing the vaccine at the end of 2020 and, in a few cases, afterwards. As we covered a lot of ground, we summarise the posts and their content in one-liners in several “posts of posts” to allow readers to get to the bottom line.
The first three posts were preceded by a consultation with you, our readers. We explained our aims, methods, and data sources. In two companion posts, we gave readers a quick explanation of regulatory terms and procedures.
We also explained that trial C4591001 was the large multicentre randomised controlled observer blind design. This meant that those dispensing and administering the vaccine could visually distinguish it from placebo.
In post 4 we raised the spectre of under reporting of potential harms and regulatory disinterest in the issue.
In post 5, we discussed the content of the vaccine: lipid nanoparticles with modified messenger RNA which is referred to…
Keep reading with a 7-day free trial
Subscribe to Trust the Evidence to keep reading this post and get 7 days of free access to the full post archives.